IPR and CBM Statistics for Final Written Decisions Issued in April 2017

Authors: Daniel F. Klodowski, Elliot C. CookDavid C. Seastrunk
Editor: Aaron L. Parker

The Patent Trial and Appeal Board issued 17 Final Written Decisions in April, cancelling 248 (86.11%) of the instituted claims while declining to cancel 30 (10.42%) of the instituted claims.  Patent owners conceded 10 (3.47%) instituted claims through motions to amend or disclaimer in cases reaching a final decision.  For comparison, the cumulative average rate of claims cancelled in final written decisions is about 74%.

On a per-case basis, no instituted or substitute claims survived in 10 (58.82%) of the decisions, all instituted claims survived in 3 (17.65%) of the decisions, and a mixed outcome occurred in 4 (23.53%) of the decisions.  A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision.

The overall cumulative instituted claim survival rate, broken down by technology center, is as follows:

More detailed cumulative statistics on the Board’s IPR and CBM decisions, updated through May 1, 2017, are available here on the AIA Blog.

Statistics regarding the outcome of appeals to the Federal Circuit are available here.

Lists of the top 10 PTAB judges by panel appearances and authored opinions are available here.

Numbers of final written decisions by technology center and instituted claim survival rates by technology center are available here.


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.

Tagged , , , , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *